艾司氯胺酮丙泊酚复合麻醉下电休克治疗伴有自杀意念重度抑郁障碍患者的效果分析

Effect Analysis of Electroconvulsive Therapy Under Combined Anesthesia of Esketamine and Propofol in Patients with Major Depressive Disorder Accompanied with Suicidal Ideation

目的比较通过不同剂量艾司氯胺酮联合电休克治疗伴有自杀意念重度抑郁障碍患者的效果,分析艾司氯胺酮作为具有抗抑郁作用特点的电休克麻醉剂,针对伴有自杀意念的重度抑郁障碍患者治疗时的优点和不足,为艾司氯胺酮在临床工作中更好地应用提供参考。方法120名患者通过随机数字表法分为对照组、低剂量组和高剂量组,每组各40例(n=40)。对照组予以丙泊酚1.2~1.5 mg/kg缓慢推注麻醉,低剂量组予以0.3 mg/kg艾司氯胺酮加1.0 mg/kg丙泊酚缓慢推注麻醉,高剂量组予以0.6 mg/kg艾司氯胺酮加0.5~0.8 mg/kg丙泊酚缓慢推注麻醉,后行无抽搐电休克治疗(MECT),治疗过程中评价疗效、安全性指标和对认知功能的影响。结果对照组、低剂量组和高剂量组患者的HAMD-24评分治疗前无明显差异,经MECT治疗后评分值逐组递减,低剂量组、高剂量组各项观察指标较对照组有差异(均P<0.05),低剂量组与高剂量组各项观察指标有差异(均P<0.05);重复性成套神经心理状态测验(RBANS)对三组患者行认知功能评估,结果显示三组患者治疗后高剂量组的RBANS评分分值明显高于低剂量组、对照组(均P<0.05);三组120例患者中没有出现严重的不良反应,三组不良反应发生率相比较,差异均无统计学意义(P>0.05);利用Beck自杀意念量表对三组患者接受治疗后自杀意念的疗效进行评估,结果显示治疗后高剂量组的Beck自杀意念量表评分分值明显低于低剂量组、对照组(均P<0.05)。结论三组患者的重度抑郁症状及自杀意念均得到改善,使用不同麻醉剂及不同剂量对伴有自杀意念的重度抑郁患者疗效随着剂量的变化呈现显著差异,且均未出现严重的不良反应,其应用到临床的安全性已得到验证,值得临床进一步推广。

Objective To analyze the effects of different doses of esketamine combined with electroconvulsive therapy on patients with major depressive disorder accompanied with suicidal ideation.Esketamine,as an electroconvulsive anesthetic with antidepressant properties,has advantages and disadvantages in the treatment of patients with major depressive disorder accompanied by suicidal ideation.It provides a reference for the better application of esketamine in clinical practice.Methods In all,120 patients were randomly divided into control group,low-dose group,and high-dose group using random number table method,with 40 cases in each group(n=40).The control group was treated with slow infusion of 1.2—1.5 mg/kg propofol,the low-dose group was treated with slow infusion of 0.3 mg/kg esketamine and 1.0 mg/kg propofol,and the high-dose group was treated with slow infusion of 0.6 mg/kg esketamine and 0.5—0.8 mg/kg propofol.The therapeutic effect,safety indicators,and impact on cognitive function were evaluated during the treatment process.Results The results of this study showed that there was no significant difference in HAMD-24 scores among control group,low-dose group,and high-dose group patients before treatment.After treatment with non-convulsive electroconvulsive therapy(MECT),the scores decreased among three groups.There were differences in various observation indicators between the low-dose group and high-dose group compared to the control group(all P<0.05),and there were differences in various observation indicators between the low-dose group and high-dose group(all P<0.05).The Repetitive Neuropsychological State Test(RBANS)was used to evaluate the cognitive function of three groups of patients.The results showed that the RBANS scores of the high-dose group were significantly higher than those of the low-dose group and control group after treatment(all P<0.05).There was no serious adverse reactions among the 120 patients in the three groups,and the incidence of adverse reactions among the three groups was not statistically significant(P>0.05).The Beck Suicide Intention Scale was used to evaluate the efficacy of suicide ideation in three groups of patients after treatment.The results showed that the Beck Suicide Intention Scale scores in the high-dose group were significantly lower than those in the low-dose group and control group(P<0.05).Conclusion The symptoms of severe depression and suicidal ideation in all three groups of patients have been improved.The efficacy of using different anesthetics and doses on patients with severe depression accompanied by suicidal ideation shows significant differences with dose changes,and no serious adverse reactions have occurred.The safety of its clinical application has been verified,and it is worth further promotion in clinical practice.